|
Mar 11
|
NVO Stock Down 9% as CagriSema Misses Target in Second Obesity Study
|
|
Mar 11
|
Morgan Stanley says REDEFINE-2 misses opportunity to differentiate in diabetes
|
|
Mar 11
|
H.C. Wainwright says Novo results support Viking obesity potential
|
|
Mar 11
|
Novo Nordisk Shares Drop After CagriSema Trial Data Falls Short of Expectations
|
|
Mar 11
|
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?
|
|
Mar 11
|
Novo Nordisk's Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trial
|
|
Mar 11
|
Trending tickers: Tesla, Nvidia, Novo Nordisk, Volkswagen and Persimmon
|
|
Mar 11
|
Is Eli Lilly Stock a Buy?
|
|
Mar 7
|
Pharma Stock Roundup: BAYRY's Q4 Results, ABBV's Obesity Deal & More
|
|
Mar 7
|
This Could Be a Huge Blow to Hims & Hers Health Stock
|
|
Mar 7
|
Wegovy's price cut, Amgen's Ozempic competitor, and Big Pharma's tax cut: Pharma news roundup
|
|
Mar 6
|
Hims & Hers' Weight-Loss Bet Hits a Wall--Is the Stock's $6 Billion Surge About to Unravel?
|
|
Mar 6
|
Novo Nordisk Faces a Perfect Storm: Tariff Shock and Legal Battle Threaten Its Blockbuster Drugs
|
|
Mar 6
|
Even weight loss drugs aren't safe from tariffs
|
|
Mar 6
|
'For Novo Nordisk, I do not worry a lot about tariffs:' CEO Lars Jørgensen
|
|
Mar 6
|
Hims & Hers Stock Is Due for a Crash Diet. The Weight-Loss Drug Surge Is Fading Fast.
|
|
Mar 6
|
Novo Nordisk Lowers Wegovy Costs for Cash-Pay Patients, Stock Up 4%
|
|
Mar 6
|
Novo Nordisk cuts Wegovy price through new direct-to-patient online pharmacy
|
|
Mar 6
|
Company News for Mar 6, 2025
|
|
Mar 6
|
Tariff Uncertainty Is Crippling Stock Markets, but Trump’s Auto Move Offers Hope. And 5 Other Things to Know Today.
|